Healthcare Equipment and Supplies
Company Overview of Pulmonx, Inc.
Pulmonx, Inc. engages in the development, manufacture, and marketing of minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. The company focuses on products to deliver endoscopic lung volume reduction to patients with emphysema-induced hyperinflation. Its products include Zephyr Endobronchial Valve, a minimally invasive device to predict and achieve reduction of volume in the diseased portion of the lung, manage hyperinflation, and treat patients with emphysema; and Chartis System, an assessment tool that provides flow and pressure readings at the lobar or segmental level for physician to make assessments regarding the level of collatera...
700 Chesapeake Drive
Redwood City, CA 94063
Founded in 1998
Key Executives for Pulmonx, Inc.
Executive Vice President and General Manager
Compensation as of Fiscal Year 2013.
Pulmonx, Inc. Key Developments
Pulmonx, Inc. Presents at Piper Jaffray 24th Annual Health Care Conference, Nov-28-2012 11:10 AM
Nov 24 12
Pulmonx, Inc. Presents at Piper Jaffray 24th Annual Health Care Conference, Nov-28-2012 11:10 AM. Venue: The New York Palace, 455 Madison Avenue, New York, NY 10022, United States.
Pulmonx, Inc. Presents at Jefferies 2012 Global Healthcare Conference, Nov-14-2012 05:00 PM
Nov 5 12
Pulmonx, Inc. Presents at Jefferies 2012 Global Healthcare Conference, Nov-14-2012 05:00 PM. Venue: The Waldorf Hilton Hotel, London, United Kingdom. Speakers: Michael A. Baker, Chief Executive Officer, President and Director.
Pulmonx, Inc. Gets United States Food and Drug Administration Approval for U.S. Trial of Emphysema Therapy
Aug 27 12
Pulmonx, Inc. announced that United States Food and Drug Administration (FDA) has approved its request for an Investigational Device Exemption (IDE) to commence a multi-center pivotal clinical trial. Pulmonx intends to use the results from this trial to support a subsequent premarket approval application (PMA) for the Zephyr(R) Endobronchial Valve (EBV). This new trial will incorporate the use of the Pulmonx Chartis System to plan valve treatment. The Zephyr Endobronchial Valve is a minimally invasive device intended to treat patients with emphysema. Emphysema patients suffer from hyperinflation, an increase in volume of the diseased portions of their lungs, which then compresses the healthier areas. The Zephyr EBV therapy involves bronchoscopic placement of one-way valves designed to reduce volume in the diseased portion of the lungs, thereby improving the ability of the healthier portions of the lungs to function. This is expected to relieve the patient's symptoms, allowing them to increase their activity levels, while promoting better overall health. The brief procedure is relatively easy for physicians to perform, and unlike other presently available Lung Volume Reduction therapies which are irreversible, the Zephyr implant can later be removed if necessary.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|